Compare CHR & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | SXTP |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | China | United States |
| Employees | 116 | 3 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | CHR | SXTP |
|---|---|---|
| Price | $2.07 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 97.2K | 52.6K |
| Earning Date | 03-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.34 |
| 52 Week High | $2.95 | $8.62 |
| Indicator | CHR | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 43.62 |
| Support Level | $0.07 | $1.30 |
| Resistance Level | $2.71 | $1.54 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 46.15 | 33.83 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.